A Study to Assess Adverse Events and Change in Disease Activity of Intravenously (IV) Infused ABBV-324 in Adult Participants With Hepatocellular Cancer (HCC) or Squamous-Cell Non-Small Cell Lung Cancer (LUSC)

Key facts

Sponsor

AbbVie

Principal Investigator

ABBVIE INC.

AbbVie

Intervention

Lenvatinib(drug)

Enrollment

232 enrolled

Eligibility

18 years · All sexes

Timeline

2025 – 2030

Study locations (22)

• City of Hope National Medical Center /ID# 270526, Duarte, California, United States
• City of Hope - Orange County Lennar Foundation Cancer Center /ID# 276120, Irvine, California, United States
• USC Norris Comprehensive Cancer Center /ID# 271573, Los Angeles, California, United States
• UC Irvine Medical Center /ID# 270507, Orange, California, United States
• UCLA - Santa Monica /ID# 275995, Santa Monica, California, United States
• University of Chicago Medical Center /ID# 270517, Chicago, Illinois, United States
• Washington University /ID# 275757, St Louis, Missouri, United States
• Memorial Sloan Kettering Cancer Center /ID# 271228, New York, New York, United States
• Thomas Jefferson University Sidney Kimmel Cancer Center /ID# 276269, Philadelphia, Pennsylvania, United States
• SCRI Oncology Partners /ID# 272750, Nashville, Tennessee, United States
• Nanfang Hospital - Southern Medical University /ID# 276916, Guangzhou, Guangdong, China
• Zhongshan Hospital Fudan University /ID# 276917, Shanghai, Shanghai Municipality, China
• Rambam Health Care Campus /ID# 270604, Haifa, Israel
• Hadassah Medical Center-Hebrew University /ID# 271235, Jerusalem, Israel
• Rabin Medical Center. /ID# 271236, Petah Tikva, Israel
• +7 more locations on ClinicalTrials.gov

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Other trials for Small cell lung cancer

Additional recruiting or active studies for the same condition.

• RECRUITINGPHASE1, PHASE2NCT06694454
  Neoadjuvant Inhaled Azacytidine With Platinum-Based Chemotherapy and Durvalumab (MEDI4736) - a Combined Epigenetic-Immunotherapy (AZA-AEGEAN) Regimen for Operable Early-Stage Non-Small Cell Lung Cancer (NSCLC)
  National Cancer Institute (NCI)
• RECRUITINGNANCT07398599
  Double-Dose Third-Generation EGFR-TKI Plus Bevacizumab and Intrathecal Chemotherapy for Refractory Leptomeningeal Metastatic NSCLC: A Phase II Study
  Second Affiliated Hospital of Nanchang University
• RECRUITINGPHASE1, PHASE2NCT07480213
  Adaptive Phase 1/2 Study of Dual-Target CAR-NK Cells in Relapsed/Refractory Small Cell Lung Cancer (SCLC)
  Beijing Biotech
• RECRUITINGPHASE1, PHASE2NCT07227597
  A Clinical Study of Gocatamig (MK-6070) and Infinatamab Deruxtecan (MK-2400) in People With Small Cell Lung Cancer (MK-6070-003)
  Merck Sharp & Dohme LLC
• RECRUITINGPHASE1NCT07348211
  First in Human Study of SIM0610 in Solid Tumors
  Jiangsu Simcere Pharmaceutical Co., Ltd.
• RECRUITINGNANCT07161310
  Urolithin A in Patients With Previously Untreated Solid Tumors Receiving Immune Checkpoint Inhibitors
  Goethe University
• RECRUITINGPHASE2NCT07304739
  Furmonertinib Combined With Intrathecal Chemotherapy and Stereotactic Radiotherapy (SRT) for EGFR-Mutated NSCLC Patients With Brain Parenchymal and Leptomeningeal Metastases
  Tianjin Medical University Cancer Institute and Hospital
• RECRUITINGPHASE1, PHASE2NCT06956690
  A Phase 1/2 Clinical Trial to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of HMBD-501 in Patients With HER3-Expressing Solid Tumors
  Hummingbird Bioscience

See all trials for Small cell lung cancer →